drugset
drugset / Trial / NCT03235570

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

NCT03235570 ↗

Phase 1 Completed 44 enrolled Incyte Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.

Timeline

Start
2017-08-01
Primary completion
2020-03-04
Completion
2020-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemigatinib Small molecule — —

Indications

cancer